The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 6, 2015, Pages

  Li, Xi ^a   Xu, Shuangnian ^a   Tan, Ya ^a   Chen, JiePing ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; IDARUBICIN; MITOXANTRONE; ZORUBICIN; ANTHRACYCLINE; ANTINEOPLASTIC ANTIBIOTIC;

ACUTE MYELOID LEUKEMIA; ADVERSE OUTCOME; ALOPECIA; BLEEDING; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; COMPARATIVE EFFECTIVENESS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; LENGTH OF STAY; LEUKEMIA; LEUKEMIA REMISSION; LIVER TOXICITY; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEPSIS; SKIN TOXICITY; STOMATITIS; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; LEUKEMIA, MYELOID, ACUTE; META ANALYSIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; DAUNORUBICIN; DOXORUBICIN; HUMANS; IDARUBICIN; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MITOXANTRONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84957789687     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010432.pub2     Document Type: Review

References (139)

1. Archimbaud E, Jehn U, Thomas X, De Cataldo F, Fillet G, Belhabri A, et al. A randomized comparison of idarubicin vs mitoxantrone, in association to VP-16 and cytarabine for induction/consolidation therapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia (AML). British Journal of Haematology 1996;Suppl 2:133.
2. Archimbaud E, Jehn U, Thomas X, De Cataldo F, Fillet G, Belhabri A, et al. Idarubicin versus mitoxantrone, in association with VP-16 and ARAC for induction/consolidation therapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia. Final analysis of a randomized trial [abstract]. Journal of Clinical Onclogy 1997:3a.
3. Archimbaud E, Jehn U, Thomas X, De Cataldo F, Fillet G, Belhabri A, et al. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leukemia 1999;13:843-9.
4. Cataldo F, Martin C, Thomas X. Idarubicin or mitoxantrone, VP-16 and cytarabine for induction/consolidation therapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia (AML): a feasibility study. Annals of Hematology 1995:a136.
5. Beksac M, Arslan O, Koc H, Akan H, Ilhan O, Arat M, et al. Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia. Medical Oncology 1998;15:183-90.
6. Beksac M, Arslan O, Koc H, Akan H, Ilhan O, Arat M, et al. A randomized single institutional study on comparison of idarubicin (I) versus daunorubicin (D) versus mitoxantrone (M) containing induction and consolidation regimens in acute myeloblastic leukemia (AML). Blood 1997, issue 10 Suppl 1 (Pt 2):237b.
7. Berman E, Gee TS, Kempin S, Gulati S, Andreeff M, Gabrilove J. Results of a comparative trial of idarubicin and cytarabine with daunorubicin and cytarabine in patients with untreated acute nonlymphocytic leukemia. Blood 1986, issue 5 Suppl 1:218a.
8. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991;77:1666-74.
9. Berman E, Raymond G, Gee TS, Kempin S, Andreeff M, Gulati S. Results of a randomized trial comparing idarubicin (IDR)/cytosine arabinoside (Ara-C) with daunorubicin (DNR)/Ara-C in adult patients (pts) with untreated acute nonlymphocytic leukemia (ANLL). Blood 1988, issue 5 Suppl 1:189a.
10. Berman E, Raymond V, Gee T, Kempin SJ, Gulati S, Andreeff M, et al. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center. Seminars in Oncology 1989;16(1 Suppl 2):30-4.
11. Bezwoda WR, Dansey RD. Idarubicin plus cytarabine versus doxorubicin plus cytarabine in induction therapy for acute non-lymphoid leukaemia: A randomized trial. Leukemia and Lymphoma 1990;1:221-5.
12. Creutzig U, Berthold F, Boos J, Fleischhack G, Gadner H, Gnekow A. Improved treatment results in children with AML: Results of study AML-BFM 93. Klinische Padiatrie 2001;213(4):175-85.
13. Creutzig U, Hermann J, Gadner H, Zimmermann M, Jurgens H, Ritter J. Comparison of equipotential doses of daunorubicin and idarubicin during induction: First results of the randomized trial BFM 93 in children with AML. Blood 1997, issue 10 Suppl 1 (Pt 1):584a.
14. Creutzig U, Ritter J, Zimmermann M, Hermann J, Gadner H, Blutters Sawatzki D, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. Leukemia 2001;15:348-54.
15. Ritter J, Zimmermann M, Creutzig U. Randomization of induction treatment with daunorubicin vs idarubicin in children with AML - Results of study AML-BFM 93. Annals of Hematology 1999:S1.
16. Creutzig U, Zimmermann M, Bourquin J-P, Dworzak MN, Fleischhack G, Graf N, et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood 2013;122:37-43.
17. Creutzig U, Zimmermann M, Dworzak M, Bourquin JP, Neuhoff C, Sander A. Study AML-BFM 2004: Improved survival in childhood acute myeloid leukemia without increased toxicity. Blood 2010;116(21):Abstract 181.
18. De Moerloose B, Suciu S, Munzer M, Piette C, Yakouben K, Margueritte G, et al. Similar efficacy and toxicity profile for idarubicin and mitoxantrone in induction and intensification treatment of children with acute myeloid leukemia (AML) or myelodysplasia (MDS): Long-term results of the EORTC-CLG randomized phase III trial 58921. Blood 2011;118:Abstract 2615.
19. Entz-Werle N, Suciu S, van der Werff ten Bosch J, Vilmer E, Bertrand Y, Benoit Y, et al. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. Leukemia 2005;19(12):2072-81.
20. Eridani S, Singh AK, Slater NGP, Pearson TC, Phaure TAJ, Semple MJ, et al. A phase II study of idarubicin versus daunorubicin in the treatment of acute non-lymphocytic leukaemia. Cancer Journal 1989;2(9):296-8.
21. Feng R, Zhang HX, Li HM. An analysis on clinical response of IA, MA and DA regimens in the treatment for acute myeloid leukemia. Journal of Oncology 2010;16(12):972-5.
22. Gardin C, Turlure P, Fagot T, Thomas X, Terre C, Contentin N, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007;109:5129-35.
23. Harousseau JL. A phase III study comparing idarubicin and rubidazone in combination with cytosine arabinoside in acute myeloid leukemia [abstract]. Haematologica 1991, issue Suppl 4:9.
24. Harousseau JL, Pignon B, Witz F, Polin V, Tellier Z, Hurteloup P, et al. Treatment of acute myeloblastic leukemia in adults. The GOELAM experience. Hematology and Cell Therapy 1996;38:381-91.
25. Indrak K, Hubacek J, Mayer J, Voglova J, Jarosova M, Krahulova M, et al. Comparison of the effectiveness of idarubicin (Zavedos) and mitoxantrone (Refador) in induction therapy of acute myeloid leukemia in elderly patients (55-75) (a prospective multicenter randomized study conducted 1998-2000. Vnitrní lékarství 2001;47(Suppl 1):48-56.
26. Intragumtornchai T, Lekhakula A, Dhamaprasit T, Sutchartichan P, Swasdikul D. Idarubicin versus doxorubicin in combination with cytarabine as first course induction therapy in acute myelogenous leukemia: a randomized controlled trial. Asian Pacific Journal of Allergy Immunology 1999:pp.23.
27. Jia Q, Ge X, Xu Y, Li C, Guan B. Comparison of domestic idarubicin and imported daunorubicin on the treatment of acute leukemia. Journal of Leukemia and Lymphoma 2011;20:747-9.
28. Lee JH, Joo YD, Kim H, Bae SH, Kim MK, Zang DY, et al. A prospective randomized comparison of idarubicin and high-dose daunorubicin in the induction chemotherapy for acute myeloid leukemia: An interim analysis. Blood 2012;120:Abstract 3628.
29. Mandelli F, Petti MC, Ardia A, Di Pietro N, Di Raimondo F, Ganzina F, et al. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA. European Journal of Cancer 1991;27:750-5.
30. Petti MC, Mandelli F. Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA. Seminars in Oncology 1989;16(1 Suppl 2):10-5.
31. Rotoli B. Idarubicin as first line treatment for adult (age 55-80) AML. conclusive results of a GIMEMA randomized trial [abstract]. Haematologica 1991, issue Suppl 4:9.
32. Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: The EORTC and GIMEMA groups study AML-10. Journal of Clinical Oncology 2009;27:5397-403.
33. Vignetti M, Witte TM, Suciu S, Zittoun R, Resegotti L, Liso V. Daunorubicin (DNR) vs mitoxantrone (MTZ) vs idarubicin (IDA) administered during induction and consolidation in acute myelogenous leukemia (AML) followed by autologous or allogeneic stem transplantation (SCT): results of the EORTC-GIMEMA. Blood 2003, issue 11 (Pt 1):175a.
34. Masaoka T, Ogawa M, Yamada K, Kimura K, Ohashi Y. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia. Seminars in Hematology 1996;33:12-7.
35. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized clinical trial of induction therapy comparing intensified daunorubicin with idarubicin in patients with previously untreated de novo acute myeloid leukemia (JALSG AML201 study) [Abstract No. 2000]. Blood 2006, issue 11 Part 1:566.
36. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: The JALSGAML201 study. Blood 2011;117:2358-65.
37. Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: Results of the ALFA-9801 study. Journal of Clinical Oncology 2010;28:808-14.
38. Pautas C, Thomas X, Merabet F, Raffoux E, Bourhis JH, Botton S, et al. Randomized comparison of standard induction with daunorubicin (DNR) for 3 days vs idarubicin (IDA) for 3 or 4 days in AML pts aged 50 to 70 and of maintenance with interleukin 2. final analysis of the ALFA 9801 study [Abstract No. 162]. Blood 2007, issue 11:55a.
39. Pignon B, Witz F, Desablens B, Leprise PY, Francois S, Linassier C, et al. Treatment of acute myelogenous leukaemia in patients aged 50-65: Idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. British Journal of Haematology 1996;94:333-41.
40. Chevallier P, Fornecker L, Lioure B, Bene MC, Pigneux A, Recher C, et al. Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: Results of the multicenter prospective phase III GOELAMS LAM-2001 trial. Leukemia 2010;24:1380-5.
41. Récher C, Béné MC, Lioure B, Pigneux A, Vey N, Delaunay J, et al. Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia. Leukemia 2014;28(2):440-3.
42. Reiffers J, Huguet F, Stoppa AM, Molina L, Marit G, Attal M, et al. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia 1996;10:389-95.
43. Reiffers J, Riga-Huguet F, Stoppa AM, Michallet M, Marit G, Attal M, et al. Idarubicin versus daunorubicin as treatment of acute myeloid leukemia in elderly patients. Haematologica 1991:8.
44. Reiffers J, Rigal-Huguet F, Stoppa AM, Michallet M, Marit G, Attal M, et al. A prospective study comparing idarubicin and daunorubicin in elderly patients with acute myeloid leukemia (AML). Annals of Hematology 1991:a2.
45. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary A, et al. A phase III study of daunorubicin vs idarubicin vs mitoxantrone for older adult patients (>55 years) with acute myelogenous leukemia (AML): A study of the Eastern Co-operative Oncology Group (E3993). Blood 1998, issue 10 Suppl 1 (Pt 1):313a.
46. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: A trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479-85.
47. Vogler WR, Velez-Garcia E, Omura G, Raney M. A phase III trial comparing daunorubicin and idarubicin in combination with cytosine arabinoside as induction therapy for acute myelogenous leukemia [abstract]. Blood 1987, issue 5 Suppl 1:240a.
48. Vogler WR, Velez-Garcia E, Omura G, Raney M. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia. Seminars in Oncology 1989;16(1 SUPPL. 2):21-4.
49. Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci A, Omura GA, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytosine arabinoside in acute myelogenous leukemia [abstract]. Haematologica 1991, issue Suppl 4:9.
50. Vogler WR, Velez-Garcia E, Weiner RS, Floum MA, Bartolucci AA, Omura GA, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group study. Journal of Clinical Oncology 1992;10:1103-11.
51. Wang WJ, Sun AN, Chou HY, Li WY. IA regimen compared with MA regimen for induction therapy of newly diagnosed acute myeloid leukemia. Chinese Journal of Hematology 2011;32(12):869-70.
52. Wiernik PH, Banks PL, Case DC, Arlin ZA. Cytarabine + idarubicin or daunorubicin for adults with previously untreated acute myeloid leukemia (AML) [abstract]. Haematologica 1991, issue Suppl 4:9.
53. Wiernik PH, Banks PLC, Case Jr DC, Arlin ZA, Periman PO, Todd MB, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992;79:313-9.
54. Wiernik PH, Case DC Jr, Periman PO, Arlin ZA, Weitberg AB, Ritch PS. A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia. Seminars in Oncology 1989;16(1 Suppl 2):25-9.
55. Belhabri A, Thomas X, Troncy J, Assouline D, Michallet M, Wattel E, et al. Continuous-infusion carboplatin in combination with idarubicin or mitoxantrone for high-risk acute myeloid leukemia: A randomised phase II study. Leukemia and Lymphoma 1999;36(1-2):45-55.
56. Buchner T, Schlenk RF, Schaich M, Dohner K, Krahl R, Krauter J, et al. Acute Myeloid Leukemia (AML): Different treatment strategies versus a common standard arm - Combined prospective analysis by the German AML Intergroup. Journal of Clinical Oncology 2012;30(29):3604-10.
57. Candoni A, Simeone E, Tiribelli M, Malagola M, Russo D, Fanin R. FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience. American Journal of Hematology 2009;84(10):690-2.
58. Castaigne S, Chevret S, Archimbaud E, Fenaux P, Bordessoule D, Tilly H, et al. Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: Long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood 2004;104(8):2467-74.
59. Chan-Lam D, Copplestone JA, Prentice A, Price R, Johnson S, Phillips M. Idarubicin cardiotoxicity in acute myeloid leukaemia. Lancet 1992;340(8812):185-6.
60. Creutzig U, Korholz D, Niemeyer CM, Kabisch K, Graf N, Reiter A, et al. 3 x 14 mg/m2 idarubicin during induction: results of a pilot study in children with AML. Leukemia 2000;14(2):340-2.
61. Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005;19(12):2030-42.
62. Dluzniewska A, Balwierz W, Armata J, Balcerska A, Chybicka A, Kowalczyk J, et al. Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia. Leukemia 2005;19(12):2117-24.
63. Gardin C, Chevret S, Pautas C, Turlure P, Raffoux E, Thomas X, et al. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. Journal of Clinical Oncology 2013;31(3):321-7.
64. Keldsen N, Karle H, Hansen NE, Nissen NI. Oral idarubicin in elderly patients with acute myeloid leukemia. European Journal of Haematology 1990;45:60.
65. Lambertenghi-Deliliers G, Annaloro C, Cortelezzi A, Cortellaro M, Della Volpe A, Maiolo AT, et al. Idarubicin plus cytarabine as first-line treatment of acute nonlymphoblastic leukemia. Seminars in Oncology 1989;16(1 Suppl 2):16-20.
66. Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S, et al. Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Blood 2008;111(3):1044-53.
67. Leone G, Sica S, Pagano L. Idarubicin including regimens in acute myelogenous leukemia in elderly patients. Critical Reviews in Oncology/Hematology 1999;32(1):59-68.
68. Li XY, Wang X, Li Y, Feng LL, Zhou H, Shan NN, et al. Analysis on clinical response of IA and DA regimens in the treatment of 74 newly diagnosed acute myeloid leukemia patients. Chinese Journal of Hematology 2013;34(1):67-8.
69. Liu Y, Ke XY, Ma J, Shen ZX, Zhang XH, Du X, et al. Multi-institutional randomized controlled clinical trial on China made 4-demethoxydaunokrubicin (IDA) in the treatment of acute leukemia. Zhonghua zhong liu za zhi [Chinese Journal of Oncology] 2005;27(12):750-2.
70. Morita Y, Kanamaru A, Miyazaki Y, Imanishi D, Yagasaki F, Tanimoto F, et al. Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group. International Journal of Hematology 2010;91(1):97-103.
71. O'Brien TA, Russell SJ, Vowels MR, Oswald CM, Tiedemann K, Shaw PJ, et al. Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group. Blood 2002;100(8):2708-16.
72. Oriol A, Ribera JM, Brunet S, Esteve J, Bueno J, Llorente A. Oral induction and consolidation chemotherapy with idarubicin and etoposide in elderly patients with acute myeloid leukemia. Haematologica 2003;88(2):229-30.
73. Pashko S, Jacobs J, Santorsa J. The cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemia. Clinical Therapeutics 1991;13(3):353-60.
74. Reinhardt D, Diekamp S, Langebrake C, Ritter J, Stary J, Dworzak M, et al. Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment. Leukemia 2005;19(8):1495-6.
75. Shi PC, Zha J, Guo XT, Chen FL, Fan ZP, Huang F, et al. Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression. Pharmacogenomics 2013;14(1):17-23.
76. Volkova MA, Kaletin GI, Pirogova NA. The comparative evaluation of the efficacy of different therapeutic plans in acute nonlymphocytic leukemias. Terapevticheskil Arkhiv 1993;65(7):18-23.
77. Wheatley K, Hills RK. Inappropriate reporting and interpretation of subgroups in the AML-BFM 93 study. Leukemia 2001;15(11):1803-4.
78. Witz F, Witz B, Dorvaux V, Paitel JF, Stockemer V, Bordigoni P, et al. Treatment of acute myeloid leukemia in adults. Results on 64 patients treated with the GOELAM 1 regimen. Annales Medicales de Nancy et de l'Est 1995;34(3):157-9.
79. Xia WL, Zhang CJ, Chen XT. Treatment of IDA on elderly patients with acute myelogenous leukemia. China Medicine and Pharmacy 2013;3(12):71-2.
80. Cooperative Study Group A for Hematology. A Prospective Randomized Comparison of Idarubicin and High-dose Daunorubicin in Combination With Cytarabine in the Induction Chemotherapy for Acute Myeloid Leukemia. www.clinicaltrials.gov/ (accessed May 19, 2010).
81. AML Collaborative Group. A systematic collaborative overview of randomised trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. British Journal of Haematology 1998;103(1):100-9.
82. Arcamone F, Bernardi L, Giardino P, Patelli B, Marco A, Casazza AM, et al. Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7, 9-diepidaunorubicin, and their beta anomers. Cancer Treatment Reports 1976;60(7):829-34.
83. Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M, et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996;88(4):1390-8.
84. Baer MR, Greer JP. Acute myeloid leukemia in adults. In: Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA editor(s). Wintrobe's Clinical Hematology. 12th Edition. Lippincott Williams & Wilkins, 2009.
85. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. British Journal of Haematology 1976;33(4):451-8.
86. Berman E, Wittes RE, Leyland-Jones B, Casper ES, Gralla RJ, Howard J, et al. Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer. Cancer Research 1983;43(12 Pt 1):6096-101.
87. Berman E, Raymond V, Daghestani A, Arlin ZA, Gee TS, Kempin S, et al. 4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia. Cancer Research 1989;49(2):477-81.
88. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992;79(12):3267-73.
89. Berman E, Wiernik P, Vogler R, Velez-Garcia E, Bartolucci A, Whaley FS. Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia. Cancer 1997;80(11 Suppl):2181-5.
90. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. Journal of Clinical Oncology 2011;29(5):487-94.
91. Carella AM, Santini G, Martinengo M, Marmont AM. 4-Demethoxydaunorubicin (idarubicin) in refractory or relapsed acute leukemias. Haematologica 1984; Vol. 69, issue 6:767-8.
92. Carella AM, Martinengo M, Santini G, Gaozza E, Damasio E, Giordano D, et al. Idarubicin in combination with etoposide and cytarabine in adult untreated acute non lymphoblastic leukemia. European Journal of Cancer and Clinical Oncology 1987;23(11):1673-8.
93. Casazza AM, Pratesi G, Giuliani F, Marco DA. Antileukemic activity of 4-demethoxydaunorubicin in mice. Tumori 1980;66(5):549-64.
94. Cersosimo RJ. Idarubicin: an anthracycline antineoplastic agent. Clinical Pharmacy 1992;11(2):152-67.
95. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta-analysis in Context. 2nd Edition. London (UK): BMJ Publishing Group, 2001.
96. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
97. Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006;107(9):2099-107.
98. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115(3):453-74.
99. Douer D, Preston-Martin S, Chang E, Nichols PW, Watkins KJ, Levine AM. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood 1996;88(1):308-13.
100. Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia 1997;11(10):1661-4.
101. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006;368(9550):1894-907.
102. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. New England Journal of Medicine 2009;361(13):1249-59.
103. Ganzina F, Pacciarini MA, Di Pietro N. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies. Investigational New Drugs 1986;4(1):85-105.
104. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490-4.
105. Jan B, Andrew O, Holger S. GRADEpro. Version 3.6 for Windows. Cochrane IMS, 2011.
106. Hande KR. Principles and pharmacology of chemotherapy. In: Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA editor(s). Wintrobe's Clinical Hematology. 12th Edition. Lippincott Williams & Wilkins, 2009.
107. Harousseau JL, Hurteloup P, Reiffers J, Rigal-Huguet F, Hayat M, Dufour P, et al. Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia. Cancer Treatment Reports 1987; Vol. 71, issue 10:991-2.
108. Hayat M, Hurteloup P, Parmentier C, Carde P, Pico JO, Schlumberger M, et al. Phase I trial of Idarubicin (4-demethoxydaunorubicin) in adult acute leukemia. Investigational New Drugs 1984; Vol. 2, issue 4:375-9.
109. Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data, In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
110. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
111. Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
112. Jabbour EJ, Estey E, Kantarjian HM. Adult acute myeloid leukemia. Mayo Clinic Proceedings 2006;81(2):247-60.
113. Johnson SA, Richardson DS. Anthracyclines in haematology: pharmacokinetics and clinical studies. Haematological Oncology 1998;12(1):52-71.
114. Kaplan S, Martini A, Varini M, Togni P, Cavalli F. Phase I trial of 4-demethoxydaunorubicin with single i.v. doses. European Journal of Cancer and Clinical Oncology 1982;18(12):1303-6.
115. Lambertenghi-Deliliers G, Maiolo AT, Annaloro C, Cortelezzi A, Pogliani E, Ganzina F, et al. Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia. European Journal of Cancer and Clinical Oncology 1987; Vol. 23, issue 7:1041-5.
116. Latagliata R, Avvisati G, Lo Coco F, Petti MC, Diverio D, Spadea A, et al. The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years. Annals of Oncology 1997;8(12):1273-5.
117. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
118. Li X, Xu SN, Tan Y, Chen JP. Idarubicin compared to other anthracyclines for treatment of newly diagnosed acute myeloid leukaemia. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD010432]
119. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology 2009;62(10):e1-34.
120. Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al. The prevention and treatment of missing data in clinical trials. New England Journal of Medicine 2012;367(14):1355-60.
121. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. New England Journal of Medicine 1999;341(14):1051-62.
122. Lowenberg B, Ossenkoppele GJ, Van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. New England Journal of Medicine 2009;361(13):1235-48.
123. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Journal of Clinical Epidemiology 2009;62(10):1006-12.
124. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 2. 2010. Available at: http://www.nccn.org/.
125. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 2. 2011. Available at: http://www.nccn.org/.
126. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 2. 2012. Available at: http://www.nccn.org/.
127. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 2. 2013. Available at: http://www.nccn.org/.
128. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
129. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
130. Robert J, Rigal-Huguet F, Hurteloup P. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. Hematological Oncology 1992;10(2):111-6.
131. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
132. Supino R, Necco A, Dasdia T, Casazza AM, Di Marco A. Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin. Cancer Research 1977;37(12):4523-8.
133. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106(4):1154-63.
134. Teuffel O, Leibundgut K, Lehrnbecher T, Alonzo TA, Beyene J, Sung L. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. British Journal of Haematology 2013;161(2):192-203.
135. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trial 2007;8:16.
136. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114(5):937-51.
137. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111(5):2505-15.
138. Wang J, Yang YG, Zhou M, Xu JY, Zhang QG, Zhou RF, et al. Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia. PloS One 2013;8(4):e60699.
139. Zittoun RA, Mandelli F, Willemze R, Witte TD, Labar B, Resegotti L, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. New England Journal of Medicine 1995; Vol. 332, issue 4:217-23.